The Office of Inspector General (OIG) has been instrumental in providing guidance to the life sciences industry, offering much more than simply a roadmap for developing robust compliance programs.
Central to this guidance are auditing and monitoring, which are considered essential components in protecting the organization against potential compliance risks.
Traditionally, monitoring and auditing have been used to detect non-compliance issues in the life sciences industry.
However, due to the manual and resource-intensive nature of monitoring and auditing, occasional lapses have occurred in the past that have led to devastating consequences.
Fast forward to today, the inception of data-driven technology changed the way life sciences companies used to pursue compliance monitoring and auditing.
It enabled them to ensure effectiveness and efficiency while significantly reducing non-compliance risks.
The OIG also recommends using data for improving compliance program capabilities, and adopting data to derive insights has proven to be highly beneficial for life sciences companies over the past past few years.
Let’s understand the perspective of OIG regarding compliance monitoring and auditing and see how compliance officers can use the guidance provided by OIG to augment their compliance program.
A Brief Introduction of the Office of Inspector General
The OIG was created by Congress in 1976 (under President Ford) to implement effective actions against fraud and abuse in the United States.
Several statutes and laws, such as the False Claims Act of 1986, HIPAA and even the Affordable Care Act mandates, have broadened the role of the OIG to fight fraud and abuse in the life sciences industry.
In addition, the Department Of Justice (DOJ) and other regulatory authorities have collaborated in the enforcement pursuit.
This has driven up the number of civil monetary penalties (CMPs) imposed on various life sciences companies due to non-compliance.
Even though life sciences companies continue to innovate healthcare by introducing novel treatments for patients, lapses have occurred where companies have had to pay millions to settle allegations.
This makes understanding and adhering to applicable rules and regulations imperative for life sciences companies.
The Role of Data in Compliance Monitoring & Auditing: OIG’s Perspective
The seven key elements of a compliance program are designed to fortify compliance programs within the life sciences sector. These elements encompass a wide array of strategies, each playing a crucial role in fostering a culture of compliance.
But more than simply a culture of compliance, the guidance provided by the OIG enables compliance officers and life sciences companies to harness the power of data to monitor, detect and remediate risks.
Data utilization has been mentioned several times in the updated compliance guidance document issued by the Office of Inspector General.
For instance, to discuss the intersection of data with an organization’s corporate compliance program, OIG has provided compliance officers and life sciences companies with a few critical questions:
- How has the company collected, tracked, analyzed, and used information from its [compliance] reporting mechanisms?
- Does the company periodically analyze the reports or investigation findings for patterns of misconduct or other red flags for compliance weaknesses?
- What has been the company’s process for tracking and remediating misconduct or misconduct risks?
- When auditing its compliance program, what testing of controls, collection and analysis of compliance data, and interviews of employees and third parties does the company undertake?
Although some pointers do not explicitly mention the importance or cruciality of leveraging data, they easily convey that regulators consider compliance data essential for ensuring compliance.
The Key Concerns Associated with Compliance Monitoring & Auditing
We’ve already established the understanding that compliance monitoring and auditing serve as vital mechanisms for evaluating the effectiveness of a compliance program and monitoring compliance throughout the organization. By systematically reviewing internal processes and procedures, organizations can identify areas of vulnerability and implement corrective measures proactively. Many organizations achieve this through outsourced compliance services, which provide scalable expertise and resources without overburdening internal teams.
By systematically reviewing internal processes and procedures, organizations can identify areas of vulnerability and implement corrective measures proactively.
They can also help assess the entire organization’s compliance stature and plan targeted activities to ensure adherence to applicable rules and regulations.
Here are a few activities that compliance officers and life sciences companies can follow to ensure effective compliance monitoring and auditing:
- Conduct regular audits of compliance and commercial activities to ensure alignment with regulatory guidelines
- Scrutinize medical affairs initiatives to uphold integrity in research and educational endeavors
- Monitor interactions with healthcare providers to foster transparency and ethical conduct
Other imperative concerns associated with compliance monitoring and auditing are mentioned below:
-
Mitigating Compliance Risks
The proactive nature of monitoring and auditing enables life sciences organizations to identify potential compliance issues before they escalate to critical levels.
Consider, for instance, the Theranos case, where the absence of robust monitoring mechanisms contributed to widespread inaccuracies in test results.
Had the organization implemented rigorous auditing protocols, such discrepancies may have been detected and rectified promptly.
-
Navigating Sales and Marketing Compliance
Sales and marketing practices in the life sciences industry are subject to complex regulatory oversight.
Monitoring and auditing these activities to ensure that they comply with laws such as the False Claims Act (FCA) ensures compliance with industry regulations and fosters transparency and trust with stakeholders and regulators.
By scrutinizing marketing materials and evaluating sales practices, organizations can mitigate non-compliance risk and safeguard their reputation and financial well-being.
-
Monitoring Interactions with Healthcare Providers
Monitoring interactions with healthcare providers (HCPs) has become a very peculiar concern over the years as regulatory authorities such as the OIG consider this a high-risk area in their compliance guidance.
Whether through educational initiatives or promotional engagements, organizations must ensure that all interactions are conducted ethically and in accordance with established guidelines.
Through regular monitoring and auditing of these interactions, organizations can mitigate the risk of potential violations and reinforce a culture of ethical conduct.
The Imperative of Proactive Compliance
In an age of complexity and heightened regulatory scrutiny, proactive identification and mitigation of compliance risks are important.
By leveraging auditing and monitoring as proactive tools, organizations can proactively address potential issues and bolster their overall compliance posture.
Moreover, integrating these mechanisms into broader compliance frameworks underscores a commitment to ethical conduct and regulatory adherence.
Conclusion
As the protectors of patient health and integrity, life sciences organizations must remain vigilant in pursuing compliance excellence.
By heeding the insights offered by the OIG and prioritizing auditing and monitoring initiatives, organizations can fortify their compliance programs and navigate the complex regulatory landscape with confidence.
In doing so, they not only safeguard against potential liabilities but also uphold the fundamental principles of integrity and accountability upon which the healthcare industry rests.